Neurologic Therapeutics in 2035: The Neurology Future Forecasting Series

Nicholas E. Johnson, Ericka Greene

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic development has accelerated rapidly in the past 5 years in many neurologic and neurodegenerative diseases. The therapeutic categories of development include small molecules, genetic therapies, and cell-based therapies. Current development has provided novel treatment approaches to disorders without available treatment. However, the regulatory procedures to allow for access to these therapies is challenging, as is the ability to provide wide access to increasingly expensive therapies. By 2035, these challenges are likely to have accelerated and have the potential to create bottlenecks in drug approval and reduced access to patients. Innovative regulatory and payer solutions are required. In addition, ethical considerations around genetic therapies should be considered in current and future development. These approaches will ensure that patients with neurologic disease have broad access to highly innovative therapies.

Original languageEnglish (US)
Pages (from-to)1121-1127
Number of pages7
JournalNeurology
Volume97
Issue number24
DOIs
StatePublished - Dec 14 2021

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Neurologic Therapeutics in 2035: The Neurology Future Forecasting Series'. Together they form a unique fingerprint.

Cite this